user

Activation of AURKA contributes to TKI resistance in EGFR-mutant non-small lung cancer

被引：0
|
作者：
Lee, Meng-Hsuan [1 ]
Hong, Shiao-Ya [2 ]
Kao, Yu-Rung [2 ]
Wu, Cheng-Wen [1 ]
机构：
[1] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan
[2] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4756
引用
收藏
页数：2
相关论文
共 50 条
  • [21] NOTCH-1 CONTRIBUTES TO EGFR-TKI ACQUIRED RESISTANCE IN NON-SMALL CELL LUNG CANCER
    Xie, M.
    Zhang, L.
    Xu, F.
    RESPIROLOGY, 2012, 17 : 89 - 89
  • [22] Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer
    Song, X.
    Zhou, C.
    Wu, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S362 - S362
  • [23] Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer
    Kaneda, Toshihiko
    Hata, Akito
    Tomioka, Hiromi
    Tanaka, Kosuke
    Kaji, Reiko
    Fujita, Shiro
    Tomii, Keisuke
    Katakami, Nobuyuki
    LUNG CANCER, 2014, 86 (02) : 213 - 218
  • [24] Immune microenvironment change after acquiring resistance to EGFR TKI therapy in EGFR mutant non-small cell lung cancer
    Kim, Tae-Jung
    Kang, Jin-Hyoung
    Hong, Sook-hee
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [25] Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells
    Namba, Kei
    Shien, Kazuhiko
    Takahashi, Yuta
    Sato, Hiroki
    Yoshioka, Takahiro
    Suzawa, Ken
    Yamamoto, Hiromasa
    Soh, Junichi
    Tomida, Shuta
    Toyooka, Shinichi
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer
    Minatta, J. N.
    Deza, D.
    Aineseder, M.
    Nunez, M. Mestas
    Mosquera, C.
    Lupinacci, L.
    Benitez, S.
    Seehaus, A.
    Luna, D.
    Beresnak, A.
    Diaz, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1166 - S1166
  • [27] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    Oncology and Therapy, 2022, 10 : 13 - 22
  • [28] Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    Soo, Ross A.
    Kim, Hye Ryun
    Asuncion, Bernadette Reyna
    Fazreen, Zul
    Omar, Mohamed Feroz Mohd
    Herrera, Maria Cynthia
    Lim, Joey Sze Yun
    Sia, Grace
    Soong, Richie
    Cho, Byoung-Chul
    LUNG CANCER, 2017, 105 : 17 - 22
  • [29] De novo MET amplification in EGFR-mutant non-small cell lung cancer
    Lee, D. D. W.
    Wang, L.
    Lai, G.
    Lim, T. K. H.
    Tan, D. S. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S1649 - S1650
  • [30] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
12345